In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker

One of the research challenges in oncology is to develop new biochemical methods for noninvasive tumor therapy evaluation to determine whether the chemotherapeutics is effective. Vascular endothelial growth factor (VEGF) was labeled with radioiodine and evaluated in vitro as well as in vivo, using A...

Full description

Saved in:
Bibliographic Details
Published in:Nuclear medicine and biology 2005-07, Vol.32 (5), p.431-436
Main Authors: Cornelissen, Bart, Oltenfreiter, Ruth, Kersemans, Veerle, Staelens, Ludovicus, Frankenne, Francis, Foidart, Jean-Michel, Slegers, Guido
Format: Article
Language:English
Subjects:
Animals
Cell Line, Tumor
Humans
Iodine Radioisotopes
Male
Melanoma - drug therapy
Melanoma - metabolism
Mice
Receptors, Vascular Endothelial Growth Factor - analysis
Tissue Distribution
Vascular Endothelial Growth Factor A - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:One of the research challenges in oncology is to develop new biochemical methods for noninvasive tumor therapy evaluation to determine whether the chemotherapeutics is effective. Vascular endothelial growth factor (VEGF) was labeled with radioiodine and evaluated in vitro as well as in vivo, using A2058, a melanoma cell line overexpressing VEGFR-1 and -2. Saturation binding analysis with [(125)I]-VEGF resulted in a K(d) of 0.1 nM. Internalization assays indicate the preserved ligand induced internalization and metabolization of the tracer. Biodistribution studies with [(123)I]-VEGF in wild type and A2058 tumor-bearing athymic mice showed low background activity and a tumor to reference tissue ratio of maximum 6.12. These results suggest that [(123)I]-VEGF is a potentially suitable tracer for tumor therapy evaluation.
ISSN:0969-8051
DOI:10.1016/j.nucmedbio.2005.03.005